A Phase 4 interventional study of Verapamil and Bisoprolol in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Morten Steen Kvistholm Jensen. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Morten Steen Kvistholm Jensen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark — 2 open to participants now, 3 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Denmark.
Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, this one is the 9th largest by planned enrollment, is one of 3 that started in 2022, is the only one in phase 4, and was the 10th registered.
364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark are open now. Recruiting first, the newest first:
Cytokinetics · Sites in Denmark, United States, Argentina and 16 more countries
Ages 18–85
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 181 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 213 across the 12 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
This is the only study on the registry with Morten Steen Kvistholm Jensen as lead sponsor.
Morten Steen Kvistholm Jensen has 1 study filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies in Cardiomyopathy, Hypertrophic with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05569382Morten Steen Kvistholm JensenTreatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim: to compare the treatment effects of Bisoprolol (beta 1 receptor specific beta blocker (BB)) and Verapamil (cardio-specific calcium channel blockers (CCB)) in patients with non-obstructive hypertrophic cardiomyopathy (HCM).
Background: Hypertrophic cardiomyopathy (HCM) is characterized by hypertrophy of the left ventricular wall and a hypercontracted state of the sarcomeres. This narrows the left ventricular cavity, but though the left ejection fraction is increased the stroke volume and the cardiac output cannot be fully compensated. The disease manifestations can be mild or develop into severe functional limitations and devastating complications at early age. Dyspnea, chest pain, palpitations and syncope are the most common symptoms, and patients are at risk of supraventricular and ventricular arrhythmias. Arrhythmias and sudden cardiac deaths may precede heart failure symptoms. Patients with symptomatic HCM are treated initially with beta blockers and calcium channel blockers. However, there is limited evidence supporting the effectiveness of this guideline-recommended treatment in HCM.
Methods: The study is a multicenter, double-blinded, randomized, placebo-controlled cross-over trial. Patients are randomized in to three 35-days treatment periods with Bisoprolol, Verapamil and Placebo. Each treatment period includes a 7-days up titration period, a 21-days target dose period and a 7-days down titration period. Between treatment periods 45 days treatment pause is allowed. End point will be evaluated at day 21 (- 4 days). Patients will be evaluated by cardiopulmonary exercise test, echocardiography, 7 day Holter-monitoring, biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ). A subgroup of patients will also be evaluated with cardiac magnetic resonance imaging.
Hypotheses: Three separate phases each with one primary effect parameters will be analyzed between treatment with Bisoprolol and Verapamil:
Phase 1: The maximal oxygen consumption (VO2 max) is different (ΔVO2 max ≥1 ml/kg/min) between treatments in non-obstructive HCM patients Phase 2: The left ventricular enddiastolic volume (LVvol) is different (ΔLVvol ≥3 ml) between treatments in non-obstructive HCM patients.
Phase 3: The incidence of non-sustained ventricular tachycardia (NSVT) is different (Hazard ratio ≥ 0.5) between treatments in non-obstructive HCM patients.
The trial will be performed and analyzed in three phases, and each phase may be unblinded and analyzed separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Maximal wall thickness ≥ 15 mm unrelated to hypertension, valve diseases or storage diseases. And one of the following:
Exclusion Criteria:
Additional exclusion criteria for CMR sub study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maximal tolerable dose (up to 360 mg per day)
Drug: Verapamil
Maximal tolerable dose (up to 7,5 mg per day)
Drug: Bisoprolol
Matching placebo
Drug: Placebo
1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration
Also known as: Isoptin Retard 240 MG, Verapamil Hydrochloride 240 MG
1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration
Also known as: Bisoprolol "Krka" 2.5 MG, Bisoprolol Fumarate 2.5 MG
1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5. week: downtitration
Also known as: Placebo oral capsule
Maximal oxygen consumption (VO2 max)
Changes in VO2 max estimated during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
Left ventricular enddiastolic volume (LVvol)
Changes in enddiastolic volume (LVvol) estimated during cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Incidence of non-sustained ventricular tachycardia (NSVT
Changes in NSVT estimated during ECG monitoring
Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Changes in KCCQ assessed by clinical evaluation
Time frame: Changes will be evaluated at day 21 in each treatment arm
New York Heart Association (NYHA) functional classification
Changes in NYHA class assessed by clinical evaluation
Time frame: Changes will be evaluated at day 21 in each treatment arm
Canadian Cardiovascular Society (CCS) class
Changes in CCS class assessed by clinical evaluation
Time frame: Changes will be evaluated at day 21 in each treatment arm
Pro-BNP/BNP
Changes in level of Pro-BNP/BNP in blood sample
Time frame: Changes will be evaluated at day 21 in each treatment arm
High sensitive Troponin I/Troponin T
Changes in level of high sensitive Troponin I/Troponin T in blood sample
Time frame: Changes will be evaluated at day 21 in each treatment arm
Metabolic equivalent of task (METs)
Changes in METs measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
Recovery time
Changes in recovery time measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
VO2 max Anaerobic threshold
Changes in VO2 max at anaerobic threshold measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
Percent predicted VO2 max
Changes in percent predicted VO2 max measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
Ventilatory equivalent for carbon dioxide VE/VCO2
Changes in VE/VCO2 measured during cardiopulmonary exercise test
Time frame: Changes will be evaluated at day 21 in each treatment arm
Echocardiographic left ventricular end-diastolic dimension
Changes in left ventricular end-diastolic dimension measured during echocardiography
Time frame: Changes will be evaluated at day 21 in each treatment arm
Echocardiographic global longitudinal strain (GLS) for LV function
Changes in GLS measured during echocardiography
Time frame: Changes will be evaluated at day 21 in each treatment arm
Echocardiographic left ventricular outflow tract time velocity intergral (LVOT VTI) for LV function
Changes in LVOT VTI measured during echocardiography
Time frame: Changes will be evaluated at day 21 in each treatment arm
Echocardiographic dimension of left atrial
Changes in left atrial dimension measured during echocardiography
Time frame: Changes will be evaluated at day 21 in each treatment arm
Episodes of atrial fibrillation (AFIB) on Holter monitoring
Changes in episodes of AFIB measured during Holter monitoring
Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm
Number of ventricular ectopic beats on Holter monitoring
Changes in number of ventricular ectopic beats measured during Holter monitoring
Time frame: Changes will be evaluated at day 21 +7 days in each treatment arm
Left ventricular systolic function on Cardiac MRI
Changes in left ventricular systolic function on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Right ventricular dimensions on Cardiac MRI
Changes in right ventricular dimensions on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Right ventricular systolic function on Cardiac MRI
Changes in right ventricular systolic function on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Stroke volume (Aortic flow) on Cardiac MRI
Changes in stroke volume (Aortic flow) on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Coronary sinus flow on Cardiac MRI
Changes in coronary sinus flow on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Dimension of inferior and superior caval vein on Cardiac MRI
Changes in dimension of inferior and superior caval vein on Cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Dimension of left atrium on cardiac MRI
Changes in dimension of left atrium on cardiac MRI
Time frame: Changes will be evaluated at day 21 in each treatment arm
Sex specific analyses of outcome measures
Changes in outcome measures between male and female
Time frame: Changes will be evaluated at day 21 in each treatment arm
Started Aug 2022 (actual). Primary completion is estimated for Apr 2027, 55 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Verapamil · Bisoprolol
Cardiomyopathy, Hypertrophic →